



**Fig. S1. IKZF2 suppression causes growth inhibition to cutaneous T cell lymphoma (CTCL) cells through promoting cell apoptosis.** (a–b) Suppression of (a) *IKZF2* RNA and (b) protein expression in Hut78 by lentiviral transduction with a shRNA sequence (shIKZF2); cells transduced with scrambled shRNA (sh0) serve as control. (c) Cell competition-based viability assay for Hut78 cells expressing the GFP-shRNA targeting endogenous *IKZF2*. The percentages of the GFP+ cells were tracked and normalized to the percentages at day 3. (d) The number of colonies formed in the colony-forming cell assay among *IKZF2*-suppressed (shIKZF2) Hut78 cells and control cells (sh0). (e) Cell Trace Far Red-based cell viability assay of *IKZF2*-suppressed (shIKZF2) Hut78 cells and control cells (sh0). Representative flow cytometry profiles of cell viability among control (sh0) and *IKZF2*-suppressed (shIKZF2) Hut78 cells. (f) 7AAD+ and Annexin V+ -based apoptosis assay of *IKZF2*-suppressed (shIKZF2) and control (sh0) Hut78 cells in flow cytometry. Representative flow cytometry profiles of cell viability among control (sh0) and *IKZF2*-suppressed (shIKZF2) Hut78 cells. (g) Cleavage of caspase-3 and cleavage of caspase-8 were detected in Hut78 cells with *IKZF2* silencing (shIKZF2) and control cells (sh0) via western blot analysis. Data are represented as means ± standard deviation (SD). Unpaired Student's *t*-test. \* *p* < 0.05; \*\**p* < 0.01; \*\*\**p* < 0.001; \*\*\*\**p* < 0.0001. ns: no significance.